-
Publication Venue For
-
Coagulopathy in COVID-19.
2020
-
Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
2020
-
RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada..
18:1507-1509.
2020
-
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19.
2020
-
Thromboinflammation and the hypercoagulability of COVID-19.
2020
-
Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH..
18:740-747.
2020
-
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study..
18:479-484.
2020
-
Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy..
18:23-35.
2020
-
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more..
17:2089-2098.
2019
-
Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation..
17:1989-1994.
2019
-
Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?.
17:1973-1978.
2019
-
The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia..
17:1956-1965.
2019
-
Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation..
17:1265-1268.
2019
-
A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes..
17:670-680.
2019
-
Derangement of the endothelial glycocalyx in sepsis..
17:283-294.
2019
-
Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH..
17:415-419.
2019
-
Laboratory criteria for antiphospholipid syndrome: reply..
16:2117-2119.
2018
-
The next best thing in factor VIIa..
16:1911-1913.
2018
-
Use of factor concentrates for the management of perioperative bleeding: reply..
16:2113-2115.
2018
-
Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity..
16:1817-1829.
2018
-
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study..
16:1069-1077.
2018
-
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency..
16:849-857.
2018
-
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH..
16:809-813.
2018
-
Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis..
16:262-270.
2018
-
Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis..
16:231-241.
2018
-
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers..
16:54-64.
2018
-
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH..
16:170-174.
2018
-
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis..
15:1913-1922.
2017
-
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release..
15:1807-1817.
2017
-
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis..
15:1322-1333.
2017
-
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran..
15:1317-1321.
2017
-
The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery..
15:57-65.
2017
-
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment..
14:2556-2559.
2016
-
An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model..
14:1249-1254.
2016
-
Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery..
14:875-885.
2016
-
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH..
14:623-627.
2016
-
Actions of thrombin in the interstitium..
14:40-47.
2016
-
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings..
13:1597-1605.
2015
-
Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages..
13:1416-1427.
2015
-
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis..
13:1010-1018.
2015
-
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study..
13:1028-1035.
2015
-
Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome..
13:398-408.
2015
-
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers..
12:1428-1436.
2014
-
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial..
12:1401-1412.
2014
-
Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH..
12:792-795.
2014
-
Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH..
11:1593-1596.
2013
-
Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer..
11:1364-1373.
2013
-
Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels..
11:1043-1052.
2013
-
Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study..
11:1194-1197.
2013
-
Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis..
10:2599-2601.
2012
-
Genome-wide association study validation identifies novel loci for atherosclerotic cardiovascular disease..
10:1508-1514.
2012
-
Mechanisms and monitoring of bypassing agent therapy..
10:1478-1485.
2012
-
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent..
10:1303-1311.
2012
-
A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins..
10:1446-1449.
2012
-
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis..
10:1242-1251.
2012
-
A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity..
10:870-880.
2012
-
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE..
10:822-832.
2012
-
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy..
10:692-694.
2012
-
High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?.
10:487-489.
2012
-
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis..
9:1902-1915.
2011
-
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses..
9:1730-1737.
2011
-
Obstetric hemorrhage..
9:1441-1451.
2011
-
Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity..
9:759-766.
2011
-
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion..
8:2642-2650.
2010
-
Inflammation does not predispose to bleeding in hemophilia..
8:2583-2585.
2010
-
Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis..
8:148-156.
2010
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients..
8:43-53.
2010
-
Platelet functions beyond hemostasis..
7:1759-1766.
2009
-
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis..
7:1737-1740.
2009
-
Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT)..
7 Suppl 1:249-252.
2009
-
The evolution of platelet-directed pharmacotherapy..
7 Suppl 1:266-271.
2009
-
Optimization of a murine immunization model for study of PF4/heparin antibodies..
7:857-864.
2009
-
Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration..
6:1453-1460.
2008
-
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor..
6:789-796.
2008
-
A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger?.
7:1514-1516.
2009